SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
Dated: September 10, 2003
Commission file number 0-21392
AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)
ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)
7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
[X] Form 20-F [ ] Form 40-F
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
[ ] Yes [X] No
Attachment:
Material Events
(a) Amarin Corporation acknowledges receipt by Watson
Pharmaceuticals of Final FDS Approval of Final FDA
approval for generic Glucotrol XL (r) 5 mg tablets.
This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by
documents or reports subsequently filed.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer
Date: September 10, 2003
Index to
Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material Event description- 4
Exhibit (a)
Contact:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com
AMARIN CORPORATION ACKNOWLEDGES RECEIPT BY WATSON
PHARMACEUTICALS OF FINAL FDA APPROVAL FOR GENERIC
GLUCOTROL XL(r) 5mg TABLETS
Tentative ANDA approval received by Watson for Glucotrol XL 10mg tablets
LONDON, United Kingdom, September 10, 2003 - Amarin Corporation plc
(NASDAQ: AMRN) today confirmed that Watson Pharmaceuticals, Inc. (NYSE:
WPI - News), a leading specialty pharmaceutical company had received approval
on its Abbreviated New Drug Application (ANDA) for 5mg glipizide extended-
release tablets from the United States Food and Drug Administration (FDA).
Additionally, Watson has received tentative approval for the 10mg strength.
As previously announced, Amarin Development AB, Amarin's Swedish
subsidiary developed the generic formulation of Watson's glipizide extended
release tablets and Amarin is entitled to a royalty on all sales of the generic
formulation as part of its agreement with Watson Pharmaceuticals. Glipizide
extended release tablets are marketed in the United States under the trade name
Glucotrol XL(r) by Pfizer, Inc.
Glucotrol XL (glipizide extended release tablets) is indicated as an
adjunct to diet for the control of hyperglycemia in patients with type-2
diabetes.
Amarin Corporation plc is a specialty pharmaceutical company focused on
neurology. The Company plans to become a leader in these therapeutic
categories by providing innovative products and solutions that address
significant unmet medical needs. Amarin has eleven pharmaceutical
products on the US market along with a development pipeline that
includes two late-stage candidates: Zelapar ( tm ) (selegiline
orally disintegrating tablets), for Parkinson's disease and
LAX-101, a proprietary compound for Huntington's Disease.
For press releases and other corporate information, visit our website at
http://www.amarincorp.com.
Statements in this press release that are not historical facts are forward-
looking statements that involve risks and uncertainties which may cause
the Company's actual results in future periods to be materially different
from any performance suggested herein. Such risks and uncertainties
include, without limitation, risks associated with the inherent uncertainty
of pharmaceutical research, product development and commercialization,
the impact of competitive products and patents, as well as other risks and
uncertainties detailed from time to time in periodic reports. For more
information, please refer to Amarin Corporation's Annual Report for 2002
on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and
Exchange Commission. The Company assumes no obligation to update
information on its expectations.